
... BIBLIOGRAPHY ...

- American Heart Association. *1998 Heart and Stroke Statistical Update*. Dallas, TX: American Heart Association, 1997.
- Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: Do rates reported in clinical trials reflect rates in primary care settings? *N Engl J Med* 1995;332:1125-1131.
- Anonymous. Cerivastatin approval expands HMG-CoA reductase inhibitor choices. *Am J Health-Syst Pharm* 1997;54:1793.
- Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. *Am J Cardiol* 1994;73:3D-11D.
- Centers for Disease Control and Prevention, National Center for Health Statistics. Vital and health statistics: Plan operation of the Third National Health and Nutrition Examination Survey, 1988-1994. DHHS Publication No. (PHS) 94-1308, Series 1, No. 324-0485. 1994. Hyattsville, MD: Department of Health and Human Services, Public Health Services, Centers for Disease Control and Prevention.
- Cullen P, Assmann G. Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: Absolute levels or extent of lowering? *Am J Cardiol* 1997;80(10):1287-1294.
- Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit. A new look at old data. *Circulation* 1995;91:2274-2282.
- Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES study). *Am J Cardiol* 1998;81:582-587.
- La Rosa JC, Hunninghake D, Bush D, et al. The cholesterol facts: A summary of the evidence relating dietary fats, serum cholesterol and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. *Circulation* 1990;81:1721-1733.
- Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? *BMJ* 1994;308:367-372.
- Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. *JAMA* 1984;251:365-374.
- Naoumova RP, Marais AD, Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolemia. *Atherosclerosis* 1996;119:203-214.
- National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). *Circulation* 1994;89:1329-1445.
- Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. *Arterioscler Thromb Vasc Biol* 1995;15:678-682.
- Nieto FJ, Alonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia: The Atherosclerosis Risk in Communities Study. *Arch Int Med* 1995;155:677-684.
- Pearson TA, Laurora IM. Treatment success in patient subgroups in the Lipid Treatment Assessment Project (L-TAP). *Circulation* 1997;96 (Suppl):1-66.
- Raasch RH. Hyperlipidemias. In Koda-Kimble MA, Young LY, eds. *Applied Therapeutics: The Clinical Use of Drugs, 5th ed*. Vancouver: Applied Therapeutics; 1993:73-1-73-15.
- Seed M, O'Connor B, Perombelon N, et al. The effect of nicotinic acid and acipimox on lipoprotein (a) concentration and turnover. *Atherosclerosis* 1993;101:61-68.
- Sempos C, Fulwood R, Haines C, et al. The prevalence of high blood cholesterol levels among adults in the United States. *JAMA* 1989;262:45-52.
- Sempos CT, Cleeman JJ, Carroll MD, et al. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. *JAMA* 1993;269(23):3009-3014.
- Spencer CM, Barradell LB, Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. *Drugs* 1996;51:982-1018.
- Superko HR, Greenland P, Manchester RA, et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. *Am J Cardiol* 1992;70:135-140.
- Woodhead GA. The management of cholesterol in coronary heart disease risk reduction. *Nurse Pract* 1996 Sep;21(9):45,48,51-3.